{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:03:27Z","timestamp":1698663807390},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T00:00:00Z","timestamp":1170806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Omenn's syndrome is a rare severe combined immunodeficiency that kills affected subjects before the end of the first year of life unless patients are treated with bone marrow transplantation (BMT). Unfortunately, post\u2010BMT patients may develop autoimmune diseases, such as autoimmune hemolytic anemia (AIHA), which sometimes fails to respond to standard therapies. Rituximab is a chimeric, human, immunoglobulin G1\/k monoclonal antibody specific for the CD20 antigen expressed on the surface of B lymphocytes. Rituximab is currently only labeled for treatment of B\u2010cell lymphoproliferative disorders, such as B\u2010cell non\u2010Hodgkin's lymphoma and follicular lymphoma; however, it is also employed in the treatment of a variety of disorders mediated by auto\u2010antibodies, such as AIHA and transplant\u2010related autoimmune disorders. Herein, we describe the case of a 23\u2010month\u2010old male child with Omenn's syndrome, who had undergone BMT and was successfully treated with rituximab (375\u2003mg\/m<jats:sup>2<\/jats:sup> intravenously, weekly for three times) for refractory post\u2010BMT hemolytic anemia. Our findings evidence that rituximab should be considered for treatment of post\u2010BMT AIHA refractory to traditional therapy also in children with primary immunodeficiencies; furthermore, rituximab might represent a means to obtain remissions without the toxic effects associated with corticosteroid and immunosuppressive agents.<\/jats:p>","DOI":"10.1111\/j.1399-3046.2007.00678.x","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T23:51:07Z","timestamp":1170892267000},"page":"552-556","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab for the treatment of post\u2010bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome"],"prefix":"10.1111","volume":"11","author":[{"given":"Briuglia","family":"Silvana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La Mazza","family":"Antonella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piraino","family":"Basilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Saija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Salpietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,7]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196508192730806"},{"key":"e_1_2_4_3_2","first-page":"2001","article-title":"Primary immunodeficiencies","volume":"68","author":"Cooper MA","year":"2003","journal-title":"Am Fam Physician"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.314"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81448-8"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.17818.x"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352405"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11302546"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104614"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2003.12.019"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.06.005"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703128"},{"key":"e_1_2_4_13_2","first-page":"157","article-title":"Differentiation of materno\u2010fetal GVHD from Omenn's syndrome in preBMT patients with severe combined immunodeficiency","volume":"14","author":"Appleton AL","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3547"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104249"},{"key":"e_1_2_4_17_2","first-page":"483","article-title":"New drugs for childhood anemia","volume":"55","author":"La Spina M","year":"2003","journal-title":"Minerva Pediatr"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000119235"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00196.x"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.04.006"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625700"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703551"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20220"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2004.12.013"},{"key":"e_1_2_4_25_2","first-page":"837","article-title":"Autoimmune hemolytic anemia with giant cell hepatitis: Case report and review of the literature","volume":"26","author":"Gorelik M","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20180"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200405000-00011"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.05.042"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2004.00158.x"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20072"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1397-3142.2003.00135.x"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3995"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3046.2007.00678.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3046.2007.00678.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:25:26Z","timestamp":1696886726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3046.2007.00678.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1111\/j.1399-3046.2007.00678.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3046.2007.00678.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,7]]}}}